Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 3% Improvement Relative Risk Çiyiltepe et al. HCQ for COVID-19 ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 147 patients in Turkey No significant difference in mortality Çiyiltepe et al., South. Clin. Ist. Euras., doi:10.14744/scie.2021.89847 Favors HCQ Favors control
The Effect of Pre-admission Hydroxychloroquine Treatment on COVID-19-Related Intensive Care Follow-up in Geriatric Patients
Çiyiltepe et al., South. Clin. Ist. Euras., doi:10.14744/scie.2021.89847
Çiyiltepe et al., The Effect of Pre-admission Hydroxychloroquine Treatment on COVID-19-Related Intensive Care Follow-up in.., South. Clin. Ist. Euras., doi:10.14744/scie.2021.89847
Apr 2021   Source   PDF  
  All Studies   Meta
Retrospective 147 ICU patients in Turkey, showing no significant difference in outcomes based on HCQ treatment before ICU admission. This is not very informative, for example we do not know if HCQ treated patients were much less likely to be admitted to the ICU. This study is excluded in the after exclusion results of meta analysis: treatment group only includes patients where treatment failed resulting in ICU admission.
risk of death, 3.2% lower, RR 0.97, p = 0.85, treatment 69 of 95 (72.6%), control 39 of 52 (75.0%), NNT 42.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Çiyiltepe et al., 30 Apr 2021, retrospective, Turkey, peer-reviewed, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: DOI: 10.14744/scie.2021.89847 South. Clin. Ist. Euras. 2021;32(3):235-240 Original Article The Effect of Pre-admission Hydroxychloroquine Treatment on COVID-19-Related Intensive Care Follow-up in Geriatric Patients Fulya Çiyiltepe,1 Ayten Saracoglu,2 Elif Bombacı,1 Kemal Saracoglu1 Department of Anesthesiology and Reanimation, University of Health Sciences, İstanbul Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey 2 Department of Anesthesiology and Reanimation, Marmara University Faculty of Medicine, İstanbul, Turkey 1 Submitted: 24.02.2021 Accepted: 30.04.2021 Correspondence: Fulya Çiyiltepe, SBÜ, İstanbul Kartal Dr. Lütfi Kırdar Şehir Hastanesi, Anesteziyoloji ve Reanimasyon Kliniği, İstanbul, Turkey E-mail: Keywords: Coronavirus; geriatrics; hydroxychloroquine; intensive care units; mortality. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Yeliz Bilir,1 ABSTRACT Objective: The admission rates to intensive care units and mortalities in geriatric patients are higher than the rest of the population with COVID-19 infection. Although the efficacy of hydroxychloroquine sulfate has been recognized, especially when started early during infection, its effectiveness at these early time points in geriatric patients has not been investigated. In this study, our primary aim was to investigate the effects of early treatment of hydroxychloroquine sulfate on COVID-19 positive geriatric patients, according to their clinical symptoms, situation before the intensive care, and patient survival. Methods: A total of 147 geriatric patients diagnosed with COVID-19 in the intensive care unit were divided into three groups: Patients who were admitted to the intensive care unit from the emergency department but did not receive treatment (Group 1); from the service for whose a 5-day treatment was initiated but not completed (Group 2); and those who completed 5-days of drug therapy (Group 3). Results: Although demographic data were similar between the three groups, the age parameters were significantly differed between them. Furthermore, there was no difference between the groups regarding mortality rate, discharge time, or extubation. The time to mortality and the duration of mechanical ventilation were found to be significantly shorter in Group 1 (p=0.001). Conclusion: No significant effect was observed on patient survival and outcome due to early administration of hydroxychloroquine sulfate.According to our main findings, this study cannot recommend pre-admission hydroxychloroquine treatment for critically ill geriatric patients with COVID-19.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop